DE69525847D1 - Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit - Google Patents

Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit

Info

Publication number
DE69525847D1
DE69525847D1 DE69525847T DE69525847T DE69525847D1 DE 69525847 D1 DE69525847 D1 DE 69525847D1 DE 69525847 T DE69525847 T DE 69525847T DE 69525847 T DE69525847 T DE 69525847T DE 69525847 D1 DE69525847 D1 DE 69525847D1
Authority
DE
Germany
Prior art keywords
compositions
alcoholism
selective serotonin
treatment
opioid antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69525847T
Other languages
English (en)
Other versions
DE69525847T2 (de
Inventor
Leonard Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
DuPont Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co, DuPont Pharmaceuticals Co filed Critical DuPont Merck Pharmaceutical Co
Publication of DE69525847D1 publication Critical patent/DE69525847D1/de
Application granted granted Critical
Publication of DE69525847T2 publication Critical patent/DE69525847T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69525847T 1994-09-19 1995-09-07 Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit Expired - Fee Related DE69525847T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19
PCT/US1995/010987 WO1996009047A1 (en) 1994-09-19 1995-09-07 Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence

Publications (2)

Publication Number Publication Date
DE69525847D1 true DE69525847D1 (de) 2002-04-18
DE69525847T2 DE69525847T2 (de) 2002-09-05

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525847T Expired - Fee Related DE69525847T2 (de) 1994-09-19 1995-09-07 Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit

Country Status (11)

Country Link
US (1) US5958962A (de)
EP (1) EP0782445B1 (de)
AT (1) ATE214276T1 (de)
AU (1) AU3419995A (de)
CA (1) CA2197554A1 (de)
CO (1) CO4410317A1 (de)
DE (1) DE69525847T2 (de)
DK (1) DK0782445T3 (de)
HR (1) HRP950485A2 (de)
WO (1) WO1996009047A1 (de)
ZA (1) ZA957891B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
WO1999001121A1 (en) 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
AU724635B2 (en) * 1997-07-01 2000-09-28 Pfizer Products Inc. Gelatine encapsulated solution dosage forms of sertraline
WO2001032178A1 (en) * 1999-10-29 2001-05-10 Novo Nordisk A/S Use of 3,4-substituted piperidines
EP2517710B1 (de) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Missbrauchssichere orale Opioidagonisten-Formulierungen
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP2301537A1 (de) 2002-05-17 2011-03-30 Duke University Zonisamid zur Behandlung von Fettleibigkeit
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
CN1784221B (zh) * 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
EP1870096A3 (de) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Zusammensetzungen zur Beeinflussung von Gewichtsverlust
EP1631799A2 (de) * 2003-06-06 2006-03-08 Combinatorx Incorporated Vorrichtung und verfahren zur mehrdimensionalen auswertung von kombinationen aus zusammensetzungen
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (de) 2004-01-13 2006-12-27 Duke University Zusammensetzungen eines antikonvulsiven mittels und eines antipsychotischen mittels zur beeinflussung des gewichtsverlustes
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2007064586A1 (en) * 2005-11-28 2007-06-07 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
AU657973B2 (en) * 1991-05-07 1995-03-30 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
HRP950485A2 (en) 1997-08-31
US5958962A (en) 1999-09-28
ATE214276T1 (de) 2002-03-15
EP0782445B1 (de) 2002-03-13
DK0782445T3 (da) 2002-05-06
ZA957891B (en) 1997-03-19
DE69525847T2 (de) 2002-09-05
CO4410317A1 (es) 1997-01-09
CA2197554A1 (en) 1996-03-28
EP0782445A1 (de) 1997-07-09
WO1996009047A1 (en) 1996-03-28
AU3419995A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
DE69525847D1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
DE60115411D1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
ATE236654T1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ES2146249T3 (es) Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
BR9508406A (pt) Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
ATE291909T1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
EA199800535A1 (ru) Способ лечения боли
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BRISTOL-MYERS SQUIBB PHARMA CO., PRINCETON, N.J.,

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee